Clinical Trial Detail

NCT ID NCT03292172
Title A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

ovarian cancer

triple-receptor negative breast cancer

Therapies

Atezolizumab + TEN-010

Age Groups: adult senior

No variant requirements are available.